Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Survey Offers Snapshot of Patient and Provider Perceptions of AI Use in Healthcare
Healthcare Technology
August 2023, Vol 14, No 4
Have you ever asked ChatGPT to create a bio on yourself? Was it spot-on? Somewhat accurate? Total fiction? ChatGPT and similar programs, such as Google’s Med-PaLM 2 and Bard, and Microsoft’s Bing Chat, are generative artificial intelligence (AI) programs that use large language models to respond to prompts.
Read More
Partnering With Patients Key to Improving Healthcare Outcomes
By
Phoebe Starr
ASCO 2023 Highlights
August 2023, Vol 14, No 4
Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.”
Read More
Ribociclib Plus Endocrine Therapy Improves Invasive Disease-Free Survival in Patients With HR-Positive, HER2-Negative, Early Breast Cancer
By
Phoebe Starr
ASCO 2023 Highlights
,
Breast Cancer
August 2023, Vol 14, No 4
Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive,
HER2
-negative, early breast cancer, according to interim results from the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting.
Read More
Final OS Analysis Confirms Benefit of Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for First-Line Treatment of Cervical Cancer
By
Phoebe Starr
ASCO 2023 Highlights
,
Cervical Cancer
,
Gynecologic Cancer
,
Women's Health
August 2023, Vol 14, No 4
Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial.
Read More
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
By
Phoebe Starr
ASCO 2023 Highlights
,
Myelodysplastic Syndromes
,
Hematologic Malignancies
August 2023, Vol 14, No 4
Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa.
Read More
Liquid Biopsies on the Horizon for Children With Solid Cancers
By
Ella Ben-Ari
Personalized Medicine
,
Pediatric Cancer
August 2023, Vol 14, No 4
Cancer researchers continue to make progress in developing tests using liquid biopsies that could complement and even serve as an alternative to traditional tissue biopsies.
Read More
Would You Trust an AI Doctor? New Research Shows Patients Are Split
Healthcare Technology
August 2023, Vol 14, No 4
Artificial intelligence (AI)-powered medical treatment options are on the rise and have the potential to improve diagnostic accuracy, but a new study led by University of Arizona Health Sciences researchers found that approximately 52% of participants would choose a human doctor rather than AI for diagnosis and treatment.
Read More
FDA Approves Columvi for Select Patients With Relapsed or Refractory Large B-Cell Lymphomas
FDA Approvals, News & Updates
,
Lymphoma
,
Hematologic Malignancies
August 2023, Vol 14, No 4
On
June 15, 2023
, the FDA accelerated the approval of glofitamab-gxbm (Columvi; Genentech), a bispecific CD20-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥2 lines of systemic therapy.
Read More
Epkinly FDA Approved for Treatment of Advanced Diffuse Large B-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
,
Hematologic Malignancies
August 2023, Vol 14, No 4
On
May 19, 2023
, the FDA accelerated the approval of epcoritamab-bysp (Epkinly; Genmab US), a bispecific CD20-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma after ≥2 lines of systemic therapy.
Read More
Lonsurf Receives New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
FDA Approvals, News & Updates
,
Colorectal Cancer
August 2023, Vol 14, No 4
On
August 2, 2023
, the FDA approved a new indication for trifluridine and tipiracil (Lonsurf; Taiho Oncology), in combination with bevacizumab (Avastin), for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti–vascular endothelial growth factor biologic therapy; and if
RAS
wild-type, an anti–epidermal growth factor receptor therapy.
Read More
Page 5 of 338
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma